⌕
NewAmsterdam Pharma · NAMS · Nasdaq
Tenet 58 · Mixed
Compare
$19.46−3.38%At closeTenet 58 · Mixed
$19.46−0.68 (−3.38%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

NewAmsterdam Pharma (NAMS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 78% below its peak, net margin −905.7%. Worth your attention in FY25: Returns vs FCF (n/m). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼50.6%
22.5
FY21→FY25CAGR +585.6%/yr
Net income ($M)▲15.6%
−203.8
FY21→FY25CAGR —
Free cash flow ($M)▲7.0%
−148.0
FY21→FY25CAGR —
Diluted EPS▲32.8%
−1.72
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Capex
$246.0K

−63.4% YoY in FY25 · 1.1% of revenue.

Returns vs FCF
n/m

$1.6M returned vs $−148.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)22.5Revenue0.0COGS22.5Gross profit−141.8R&D−106.4SG&A−225.7Op income21.9Tax & other−203.8Net income

-906¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -905.7% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
25,937.022,503.045,563.014,090.0102,694.010.2▼50.6%+585.6%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
25,937.022,503.045,563.014,090.0102,694.010.2▼50.6%+585.6%
Research & development
157,633.0141,832.0151,406.0159,424.086,744.028,331.2▼6.3%+49.6%
Selling, general & admin
101,755.0106,354.070,446.037,633.019,507.05,436.0▲51.0%+110.3%
Total operating expenses
259,388.0248,186.0221,852.0197,057.0106,251.033,767.3▲11.9%+64.7%
Operating incomefeeds ROC rank
−233,451.0−225,683.0−176,289.0−182,967.0−3,557.0−33,757.1▼28.0%—
Other income, net
29,770.021,864.0−65,310.06,057.0−19,077.01,388.7——
Pretax income
−203,681.0−203,819.0−241,599.0−176,910.0−22,634.0−32,368.3▲15.6%—
Income tax
1,207.00.0−1.027.00.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−204,888.0−203,819.0−241,598.0−176,937.0−22,634.0−32,368.3▲15.6%—
Per share
Diluted EPSbuyback-sensitive
−1.68−1.72−2.56−2.15−1.19−1.37▲32.8%—
Diluted shares (mn)
119.93114.98109.8289.2781.56—▲4.7%+12.1%
Margins
Gross margin
100.0%100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
−900.1%−1002.9%−386.9%−1298.6%−3.5%−331406.5%▼616.0pp+330403.6pp
Net margin3rd pct in Healthcare
−789.9%−905.7%−530.3%−1255.8%−22.0%−317772.9%▼375.5pp+316867.2pp
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-18 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was NewAmsterdam Pharma's revenue last fiscal year?

NewAmsterdam Pharma reported revenue of $22.5M in fiscal 2025, down 50.6% from fiscal 2024.

What was NewAmsterdam Pharma's net income?

NewAmsterdam Pharma reported net income of −$203.8M in fiscal 2025, a net margin of −905.7%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.